Board summary
Key figures
45,238
Registered population
58.2% aged 18–64
21.9%
Aged 65+
ICB 14.9% · England 17.9%
11.8%
Ethnic minority (non-White)
6.6% Asian · England 9.6%
19.5%
In IMD quintile 1
ICB 40.7% · England 21.0%
~8,940
Core20 residents (est.)
Resident basis; registered basis ~9,389 · see page 3
7,541
Hypertension register
+8.35% in 3 yrs · England +5.60%
336
SMI register
9.3% of Bolton (LAD)'s
1,002
COPD register
Reviews -3.99% in 3 yrs
Forecast to 2030
9,053
Hypertension patients, 2030
+1,512 on today
58.8%
QRISK ≥20% on statins, 2030
+1.22pp over 3 yrs
5.3%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Lipid therapy lags across high-risk cohorts.
QRISK ≥ 20% lipid therapy is 56.3% (England 63.6%) and CKD is 64.0% (England 70.3%), which may reflect recall gaps requiring local audit.
Annual review rates fell from 2023 to 2025.
Three-year changes were -1.5% for heart failure (England +8.7%), -2.4% for asthma (England +4.4%) and -4.0% for COPD (England +2.8%).
Hypertension blood pressure control exceeds comparators.
Blood pressure control reaches 71.7% (Bolton 69.7%, ICB 71.4%, England 70.3%), alongside 77.5% breast screening coverage (England 69.9%).
Population, age and ethnicity
With 21.9% aged 65+, Turton PCN has an older, predominantly White population
Turton PCN serves 45,238 registered patients, with an older profile: 21.9% (9,925 patients) are aged 65+, exceeding Bolton (14.7%), NHS Greater Manchester ICB (14.9%) and England (17.9%). Projected list growth to 2030 is 1.3% (Bolton 1.3%, ICB 1.6%, England 2.3%, unverified methodology). In associated resident areas (Census basis, not registered patients), 88.2% are White, above Bolton (72.0%), the ICB (76.4%) and England (81.1%), while Asian / Asian British residents comprise 6.6% (Bolton 20.1%, ICB 13.6%, England 9.6%).
Age profile
65+: ICB 14.9%, England 17.9%
Ethnicity
Older people · falls rows are Bolton (LAD) local-authority (LA) data, not PCN
| Measure | Local | North West | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Bolton LA) | 1,923 | 2,071 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 80.6% | 82.9% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 56.1% | 56.6% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Bolton LA) | 958 | 1,021 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Bolton LA) | 19.0 | 18.2 | 14.8 | 2022‑24 |
Deprivation and Core20
Core20 share is 19.5% overall but practice shares span 47.1 percentage points
Turton PCN's Core20 share is 19.5%, below Bolton (47.8%), NHS Greater Manchester ICB (40.7%) and England (21.0%), with an average IMD decile of 6.2. Across practices, shares span a 47.1 pp range. Crompton View Surgery records 47.1% (2,867 estimated patients) and Harwood Medical Centre records 31.1% (3,779 estimated patients), whereas Edgworth Medical Centre and Bromley Meadows Surgery record 0.0%. The PCN rate and practice-weighted share (20.8%) differ by 1.27 percentage points. Delivery may need to balance patient concentration against volume across these practices.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
336
SMI register
0.75% recorded prevalence
211
Learning disability register
0.47% recorded prevalence
7
Care homes, 252 beds
In the PCN catchment
9.8%
Provide unpaid care
Bolton (LAD), Census 2021
Turton PCN records 211 learning disability patients (0.5% vs England 0.6%) and 336 severe mental illness patients (0.8% vs England 1.0%), alongside 7 care homes with 252 beds in its catchment. For Bolton, the autumn 2025 snapshot recorded 5 people sleeping rough, while the borough unpaid carer rate was 9.8% (unpaid carers were not captured at PCN level).
Severe mental illness: physical health checks
SMI blood pressure checks reached 87.1% (England 83.4%), while BMI checks rose +0.3 pp over 2023 to 2025 (England +5.1 pp). Psychosis alcohol recording is 80.3% (England 81.8%). Annual physical health recording lags national gains despite strong blood pressure monitoring.
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
7,541
Hypertension register
+8.35%
Register growth, 3 yrs
Bolton (LAD) +4.70% · England +5.60%
+1.59pp
BP control, under 80
≤140/90 · +0.83pp aged 80+
+1,512
More patients by 2030
Forecast 9,053 (19.63%)
Hypertension case-finding and control
Turton PCN records a hypertension prevalence of 16.7% (7,541 patients), above Bolton (14.8%), NHS Greater Manchester ICB (14.4%) and England (15.2%). Blood pressure monitoring reached 91.7% (England 90.0%), and 71.7% are treated to target (England 70.3%). Among patients under 80, control is 68.3% (England 67.8%), and for those aged 80 and over it is 83.3% (England 81.2%). However, recent reading growth over 2023 to 2025 (+1.9%) trailed England (+3.6%). Crude rates exclude unrecorded need, and denominators include personalised care adjustments. Higher blood pressure control than national benchmarks provides a solid foundation, but slower recent review growth means clinicians should ensure annual blood pressure monitoring keeps pace across all practices.
Lipids and statins
Turton PCN trails England on lipid therapy: QRISK ≥ 20% reaches 56.3% (England 63.6%), CKD 64.0% (England 70.3%), diabetes without CVD 67.3% (England 73.2%), and diabetes with CVD 80.0% (England 84.4%). Fewer at-risk patients receive lipid-lowering therapy than national rates imply, making a systematic statin recall audit the primary clinical priority.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 65,480 | £2.20 | £1.94 | £1.86 | £144,056 |
| Cardiovascular (all), 2025 | 105,693 | £4.85 | £3.15 | £3.33 | £512,611 |
In 2026, the PCN prescribed 65,480 lipid-modifying items at £2.20 per item, above Bolton (£1.81), NHS Greater Manchester ICB (£1.94) and England (£1.86). Spending was £22,263 more than at England's unit cost. Higher unit costs alongside lower treatment coverage indicate an opportunity to review formulary choices and align prescribing with lower-cost regimens.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
−2.44%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
+0.79%
Asthma prevalence, PCN 3-yr % change
Asthma prevalence is 7.6% (3,235 patients) and COPD prevalence is 2.2% (1,002 patients). Although annual reviews exceed England—asthma at 68.4% (England 65.7%) and COPD at 77.9% (England 76.4%)—both fell over 2023 to 2025: asthma fell 2.4% (England +4.4%) and COPD fell 4.0% (England +2.8%). An estimated 1,023 asthma patients remain unreviewed, while youth asthma prescribing is 1,949 items per 1,000 population aged 5 to 19 (England 1,488). Falling review rates alongside higher youth prescribing could reflect delivery strain, which capacity audits could test.
Cancer register and children's immunisation
Cancer register prevalence is 4.3% (1,959 patients), above England (3.8%). In childhood immunisation, age-5 MMR dose 1 is 97.7% (England 91.7%), exceeding the 95.0% target by 2.7 pp. However, dose 2 is 90.6% (below target by 4.4 pp), reflecting a 7.1 pp drop between doses. The 4-in-1 booster coverage is 89.1% (below target by 5.9 pp). Timely completion before school entry requires focused recall to close the second-dose protection gap.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
55.6%
Greater Manchester ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~2,270
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Greater Manchester ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Lung | 40.4% | 33.8% | 15% | 2,193 |
| Prostate | 61.7% | 53.2% | 14% | 1,788 |
| Breast | 82.5% | 85.4% | 19% | 1,758 |
| Bowel | 46.3% | 47.0% | 19% | 1,427 |
| Skin cancer | 84.5% | 87.8% | 27% | 580 |
In 2022, 55.6% of cancers with a known stage in NHS Greater Manchester ICB were diagnosed at stage 1 or 2 (6,491 of 11,679 staged cancers), in line with England (55.3%) but 19.4 pp below the 75.0% national ambition. Known stage was recorded for 70.8% of 16,492 registered cancers (England 67.0%). Reaching 75.0% requires about 2,270 extra early-stage cases ICB-wide. Locally, breast screening is 77.5% (England 69.9%) and cervical screening is 73.2% (England 66.8%), though cervical screening coverage fell 2.3% (England -1.0%) over 2023 to 2025. System stage data describes the ICB rather than PCN performance.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
In Jul 2026 (provisional), Bolton NHS Foundation Trust achieved 80.5% on the 28-day faster diagnosis standard (standard 75.0%), ahead of NHS Greater Manchester Integrated Care Board (79.5%) and England (79.3%). However, 62-day referral to treatment was 69.7%, trailing East Lancashire Hospitals NHS Trust (73.2%), Northern Care Alliance NHS Foundation Trust (78.6%), the ICB (75.7%) and England (71.2%), falling 15.3 pp below the 85.0% standard. Bolton NHS Foundation Trust met the 31-day standard at 96.5% (standard 96.0%). Six-week diagnostic waits reached 25.3% for cystoscopy and 2.0% for MRI (England 21.4%). Provider waiting times describe trust performance rather than PCN delivery.
| Pathways within standard (%) | Bolton | Northern Care Alliance | East Lancashire | Greater Manchester ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 80.48 | 75.20 | 81.50 | 79.53 | 79.32 |
| 31-day treatment (96%) | 96.50 | 94.54 | 98.11 | 96.49 | 92.50 |
| 62-day referral to treatment (85%) | 69.66 | 78.65 | 73.16 | 75.73 | 71.16 |
| Diagnostic waits over 6 weeks (%) | Bolton | Northern Care Alliance | East Lancashire | England |
|---|---|---|---|---|
| MRI | 2.05 | 5.09 | 0.43 | 21.40 |
| CT | 19.40 | 4.10 | 0.15 | 9.92 |
| Echocardiography | 3.48 | 31.48 | 0.00 | 28.48 |
| Colonoscopy | 1.33 | 40.04 | 0.95 | 30.83 |
| Gastroscopy | 2.06 | 36.48 | 1.16 | 29.02 |
| All 15 DM01 tests | 15.78 | 15.71 | 3.25 | 23.14 |
| Community services activity | Bolton residents | Greater Manchester ICB |
|---|---|---|
| Care contacts | 49,315 | 573,310 |
| Referrals | 4,075 | 94,470 |
| Patients with a contact | 17,765 | 183,535 |
Community services (residents of Bolton), Jun 2026 (provisional). In Jun 2026 (provisional), adults aged 65 and over accounted for 51.6% of all community service contacts among borough residents (25,460 of 49,315 contacts). Community provider activity was not captured at PCN level, representing wider borough resident activity rather than Turton PCN patients directly.
Practice variation and patient experience
Patient experience spans 28.0 pp across practices despite clinical achievement reaching 100.0%
In 2025/26, overall QOF achievement ranged from 87.1% at Edgworth Medical Centre to 97.5% at Crompton View Surgery, against 92.5% in England. Vaccination and immunisation achievement showed a 42.7 pp spread, from 35.3% at The Oaks Family Practice to 78.0% at Crompton View Surgery (England 55.2%). Clinical domain scores reached 100.0% at Mandalay Medical Centre.
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Crompton View | 95 | 47.1 | 83.1% | 76.4% | 98.1% |
| Edgworth | 121 | 0.0 | 87.1% | 84.9% | 95.5% |
| Bromley Meadows | 113 | 0.0 | 73.1% | 75.5% | 92.1% |
| Mandalay | 109 | 5.7 | 56.8% | 74.5% | 79.2% |
| Harwood | 126 | 31.1 | 52.5% | 87.3% | 72.2% |
| Oaks | 97 | 33.1 | 59.5% | 71.2% | 70.1% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Sixteen of 25 measures trail England's change as annual chronic disease reviews fall
Across 2023 to 2025, 16 of 25 measures trail England's change. The sharpest lags appear in annual reviews: heart failure reviews fell 1.5% (England +8.7%), asthma reviews fell 2.4% (England +4.4%), and COPD reviews fell 4.0% (England +2.8%). Mental health physical checks lagged on alcohol recording, which fell 0.1 pp (England +5.4 pp), and BMI recording, which rose 0.3 pp (England +5.1 pp). Severe mental illness blood pressure checks rose 5.0 pp (England +4.4 pp).
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Heart failure reviews
Asthma reviews
COPD reviews
Alcohol record (psychosis)
BMI record (SMI)
BP check (SMI)
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Bolton (LAD) | Asset | PCN | Bolton (LAD) |
|---|---|---|---|---|---|
| Care homes (catchment) | 7 (252 beds) | n/a | Schools (catchment) | 51 | n/a |
| Children's centres | 4 | 18 | Places of worship | 29 | 144 |
| Libraries | 2 | 7 | Primary schools (LA maintained) | 13 | 61 |
| Primary academies | 10 | 32 | Special schools | 1 | 3 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Statin recall and formulary review
Lipid therapy trails England across four QOF cohorts: QRISK ≥ 20% at 56.3% (England 63.6%), CKD 64.0% (70.3%), diabetes without CVD 67.3% (73.2%) and with CVD 80.0% (84.4%). Unit cost is £2.20 (£22,263 more than England's unit cost across 65,480 items). Moderate effort to run.
Evidence base: the hypertension register is the cohort for case-finding, blood-pressure control and AF anticoagulation; its size and growth set the workload those interventions must cover, and a shortfall in control shows up later as emergency admission.
Policy anchor: Core20PLUS5 (hypertension case-finding and optimal management); NHS CVD ambitions to 2029 on detection, treatment to target and statins for high-risk patients (CVDPREVENT).
Option 2
Chronic disease annual review recall
Over 2023 to 2025, reviews fell while England's rose: asthma fell 2.4% (England +4.4%; current 68.4%, 1,023 of 3,235 register patients unreviewed), COPD fell 4.0% (England +2.8%; current 77.9%) and heart failure fell 1.5% (England +8.7%; current 83.3%). Moderate effort to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 3
Learning disability register validation
Recorded learning disability prevalence is 0.5% (211 of 45,238 patients), below Bolton (0.6%) and England (0.6%), giving an unadjusted benchmark gap of +55 (England) to +63 (Bolton) patients despite +20.1% growth over 2023 to 2025. Low cost, quick to run.
Evidence base: the register is the cohort for the annual health check and LeDeR learning; people with a learning disability die on average 20 years earlier and are a Core20PLUS5 PLUS group.
Policy anchor: annual health checks for 75% of people aged 14+ on the register (Network Contract DES); Oliver McGowan mandatory training.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Older population proactive care review (p2) | Aged 65+ | Neighbourhood health framework · NHS vaccination strategy | PCN |
| Targeted Core20 preventive outreach (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| SMI physical check protocol (p4) | Record of BMI in the last 12 months for patients on the MH register (denominator incl. PCAs) | MHIS · From Harm to Hope | PCN |
| Annual blood pressure review audit (p5) | Hypertension patients with a recent blood pressure reading | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Pre-school booster recall audit (p6) | MMR dose 2 coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Cervical screening recall audit (p7) | Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026 | PCN |
| Telephony and triage review (p9) | GPPS easy to contact the practice by phone | 10YHP, hospital to community | Practice |
| Option 1 · Statin recall and formulary review (p12) | Hypertension: QOF prevalence · Patients with QRISK ≥ 20% treated with lipid lowering therapy · CKD patients treated with lipid lowering therapy | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Option 2 · Chronic disease annual review recall (p12) | Asthma register · COPD register · Heart failure register | Core20PLUS5 respiratory | PCN |
| Option 3 · Learning disability register validation (p12) | Learning disability register · Learning disability: QOF prevalence · Registered population | 75% annual health checks (Network Contract DES) · Oliver McGowan | PCN |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | Local authority | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
